Какие неблагоприятные реакции на генно-инженерные биологические препараты относят к парадоксальным?
Аннотация
В статье обсуждается появление необычных – парадоксальных – неблагоприятных реакций, возникающих в результате лечения ревматических болезней генно-инженерными биологическими препаратами.
Об авторе
Ю. В. Муравьев
ФГБНУ «Научноисследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия
Россия
Список литературы
1. Toussirot E, Aubin F. Paradoxical reactions under TNF-blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2(2):e000239. doi: 10.1136/rmdopen-2015-000239
2. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5:421-31. doi: 10.1586/eci.09.18
3. Toussirot E, Pertuiset E. TNF blocking agents and sarcoidosis: an update. Rev Med Interne. 2010;31:828-37. doi: 10.1016/j.revmed.2010.02.007
4. Joyau C, Veyrac G, Dixneuf V, et al. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012;30:700-6.
5. Fouache D, Goёb V, Massy-Guillemant N, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford). 2009;48:761-4. doi: 10.1093/rheumatology/kep083
6. Baeten D, Kruithof E, van den Bosch F, et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis. 2003;62:829-34. doi: 10.1136/ard.62.9.829
7. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001. doi: 10.1002/art.23835
8. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-40. doi: 10.1016/j.semarthrit.2010.04.003
9. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-55. doi: 10.1016/j.cgh.2010.07.022
10. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-15. doi: 10.1136/ard.2007.087288
11. Hernandez MV, Sanmarti R, Canete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013 Dec;65(12):2024-31. doi: 10.1002/acr.22096
12. Thomas L, Canoui-Poitrine F, Gottenberg JE, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry.J Rheumatol. 2012 May;39(5):893-8. doi: 10.3899/jrheum.111347. Epub 2012 Apr 15.
13. Lie E, Lindströ m U, Zverkova-Sandströ m T, et al. The effect of TNF inhibitor treatment on occurrence of anterior uveitis in anky-losing spondylitis: results from the Swedish biologics register. Arthritis Rheum. 2015;67:1271-2.
14. Jimenez-Boj E, Stamm TA, Sadlonova M, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis. 2012;71:1868-71. doi: 10.1136/annrheumdis-2012-201897
15. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56:2715-18. doi: 10.1002/art.22811
16. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month,multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176
17. Jost C, Hermann J, Caelen Lel-S, et al. New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis. BMJ Case Rep. 2009;2009. pii: bcr09.2008.0845.
18. Kato K, Satoh T, Nishizawa A, Graninger W. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol. 2011;91:362-3. doi: 10.2340/00015555-1042
19. Florent A, Albert C, Giacchero D, Graninger W. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine. 2010;77:626-7.
20. doi: 10.1016/j.jbspin.2010.09.015
21. Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol. 2010;90:183-5. doi: 10.2340/00015555-0777
22. Laurent S, Le Parc JM, Clerici T, et al. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol. 2010;163:1364-5. doi: 10.1111/j.1365-2133.2010.10005.x
23. Palmou-Fontana N, Sanchez Gavino JA, McGonagle D, et al. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology (Basel). 2014;228:311-3. doi: 10.1159/000362266
24. Puig L, Morales-Munera CE, Lopez-Ferrer A, et al. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in apatient with psoriatic arthritis: case report and review. Dermatology (Basel). 2012;225:14-7. doi: 10.1159/000339864
25. Hay RA, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol. 2014;39:751-2. doi: 10.1111/ced.12392
26. Carija A, Ivic I, Marasovicc-Krstulovicc D, et al. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab. Rheumatology (Oxford). 2015;54:2114-6. doi: 10.1093/rheumatology/kev263
27. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503. doi: 10.1038/nrgastro.2012.125
28. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch
29. Ophthalmol. 2009;127:819-22. doi: 10.1001/archophthalmol.2009.141
30. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317-23. doi: 10.1016/j.ophtha.2006.04.038
31. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65:1631-4. doi: 10.1136/ard.2006.052092
32. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696-701. doi: 10.1136/ard.2008.092585
33. Le Garrec J, Marcelli C, Mouriaux F. Can tumor necrosis factor inhibitors induce sclero-uveitis? J Fr Ophtalmol. 2009;32:511.e1-6.
34. Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41:503-10. doi: 10.1016/j.semarthrit.2011.05.005
Рецензия
Для цитирования:
Муравьев Ю.В. Какие неблагоприятные реакции на генно-инженерные биологические препараты относят к парадоксальным? Научно-практическая ревматология. 2018;56(4):531-534. https://doi.org/10.14412/1995-4484-2018-531-534
For citation:
Muravyev Yu.V. WHAT ADVERSE REACTIONS TO BIOLOGICAL AGENTS ARE PARADOXICAL? Rheumatology Science and Practice. 2018;56(4):531-534. (In Russ.) https://doi.org/10.14412/1995-4484-2018-531-534
Просмотров: 611
Послать статью по эл. почте 
